Table 2.
Prevalence of key FcγR genotypes in the GALLIUM and GOYA trials
| GALLIUM* | GOYA† | |||||
|---|---|---|---|---|---|---|
| Genotype | Total | R | G | Total | R | G |
| FCGR2A | n = 1144 | n = 571 | n = 573 | n = 1316 | n = 658 | n = 658 |
| R131R | 231 (20.2) | 117 (20.5) | 114 (19.9) | 291 (22.1) | 138 (21.0) | 153 (23.3) |
| R131H | 547 (47.8) | 270 (47.3) | 277 (48.3) | 595 (45.2) | 282 (42.9) | 313 (47.6) |
| H131H | 366 (32.0) | 184 (32.2) | 182 (31.8) | 430 (32.7) | 238 (36.2) | 192 (29.2) |
| FCGR2B | n = 1062 | n = 532 | n = 530 | n = 1080 | n = 546 | n = 534 |
| I232I | 823 (77.5) | 406 (76.3) | 417 (78.7) | 773 (71.6) | 396 (72.5) | 377 (70.6) |
| I232T | 220 (20.7) | 116 (21.8) | 104 (19.6) | 282 (26.1) | 137 (25.1) | 145 (27.2) |
| T232T | 19 (1.8) | 10 (1.9) | 9 (1.7) | 25 (2.3) | 13 (2.4) | 12 (2.3) |
| FCGR3A | n = 1144 | n = 571 | n = 573 | n = 1313 | n = 656 | n = 657 |
| F158F | 479 (41.9) | 256 (44.8) | 223 (38.9) | 591 (45.0) | 285 (43.5) | 306 (46.6) |
| F158V | 521 (45.5) | 238 (41.7) | 283 (49.4) | 574 (43.7) | 296 (45.1) | 278 (42.3) |
| V158V | 144 (12.6) | 77 (13.5) | 67 (11.7) | 148 (11.3) | 75 (11.4) | 73 (11.1) |
Data are number of patients (percentage of the subgroup).
G, obinutuzumab; R, rituximab.
*
Data missing for GALLIUM (n): FCGR2A, 58 (total), 30 (R), and 28 (G); FCGR2B, 140 (total), 69 (R), 71 (G); FCGR3A, 58 (total), 30 (R), 28 (G).
†
Data missing for GOYA (n): FCGR2A, 98 (total), 52 (R), 46 (G); FCGR2B, 334 (total), 164 (R), 170 (G); FCGR3A, 101 (total), 54 (R), 47 (G).